1
|
He Y, Chu Y, Guo S, Hu J, Li R, Zheng Y, Ma X, Du Z, Zhao L, Yu W, Xue J, Bian W, Yang F, Chen X, Zhang P, Wu R, Ma Y, Shao C, Chen J, Wang J, Li J, Wu J, Hu X, Long Q, Jiang M, Ye H, Song S, Li G, Wei Y, Xu Y, Ma Y, Chen Y, Wang K, Bao J, Xi W, Wang F, Ni W, Zhang M, Yu Y, Li S, Kang Y, Gao Z. T2T-YAO: A Telomere-to-telomere Assembled Diploid Reference Genome for Han Chinese. GENOMICS, PROTEOMICS & BIOINFORMATICS 2023; 21:1085-1100. [PMID: 37595788 PMCID: PMC11082261 DOI: 10.1016/j.gpb.2023.08.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 08/01/2023] [Accepted: 08/08/2023] [Indexed: 08/20/2023]
Abstract
Since its initial release in 2001, the human reference genome has undergone continuous improvement in quality, and the recently released telomere-to-telomere (T2T) version - T2T-CHM13 - reaches its highest level of continuity and accuracy after 20 years of effort by working on a simplified, nearly homozygous genome of a hydatidiform mole cell line. Here, to provide an authentic complete diploid human genome reference for the Han Chinese, the largest population in the world, we assembled the genome of a male Han Chinese individual, T2T-YAO, which includes T2T assemblies of all the 22 + X + M and 22 + Y chromosomes in both haploids. The quality of T2T-YAO is much better than those of all currently available diploid assemblies, and its haploid version, T2T-YAO-hp, generated by selecting the better assembly for each autosome, reaches the top quality of fewer than one error per 29.5 Mb, even higher than that of T2T-CHM13. Derived from an individual living in the aboriginal region of the Han population, T2T-YAO shows clear ancestry and potential genetic continuity from the ancient ancestors. Each haplotype of T2T-YAO possesses ∼ 330-Mb exclusive sequences, ∼ 3100 unique genes, and tens of thousands of nucleotide and structural variations as compared with CHM13, highlighting the necessity of a population-stratified reference genome. The construction of T2T-YAO, an accurate and authentic representative of the Chinese population, would enable precise delineation of genomic variations and advance our understandings in the hereditability of diseases and phenotypes, especially within the context of the unique variations of the Chinese population.
Collapse
Affiliation(s)
- Yukun He
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China
| | - Yanan Chu
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China
| | - Shuming Guo
- Linfen Clinical Medicine Research Center, Linfen 041000, China; Institute of Chest and Lung Diseases, Shanxi Medical University, Taiyuan 030001, China
| | - Jiang Hu
- GrandOmics Biosciences Co., Ltd, Wuhan 430076, China
| | - Ran Li
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Yali Zheng
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Xinqian Ma
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Zhenglin Du
- Institute of PSI Genomics, Wenzhou 325024, China
| | - Lili Zhao
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Wenyi Yu
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Jianbo Xue
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Wenjie Bian
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Feifei Yang
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Xi Chen
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Pingan Zhang
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Rihan Wu
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Yifan Ma
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Changjun Shao
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China
| | - Jing Chen
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China
| | - Jian Wang
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China
| | - Jiwei Li
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Jing Wu
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Xiaoyi Hu
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Qiuyue Long
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Mingzheng Jiang
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Hongli Ye
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Shixu Song
- Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China
| | - Guangyao Li
- Linfen Clinical Medicine Research Center, Linfen 041000, China
| | - Yue Wei
- Linfen Clinical Medicine Research Center, Linfen 041000, China
| | - Yu Xu
- Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China
| | - Yanliang Ma
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Yanwen Chen
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Keqiang Wang
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Jing Bao
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Wen Xi
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Fang Wang
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Wentao Ni
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Moqin Zhang
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Yan Yu
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Shengnan Li
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China
| | - Yu Kang
- CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100490, China.
| | - Zhancheng Gao
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; Institute of Chest and Lung Diseases, Shanxi Medical University, Taiyuan 030001, China; Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing 100101, China.
| |
Collapse
|
2
|
Manjunath V, Thenral SG, Lakshmi BR, Nalini A, Bassi A, Karthikeyan KP, Piyusha K, Menon R, Malhotra A, Praveena LS, Anjanappa RM, Murugan SMS, Polavarapu K, Bardhan M, Preethish-Kumar V, Vengalil S, Nashi S, Sanga S, Acharya M, Raju R, Pai VR, Ramprasad VL, Gupta R. Large Region of Homozygous (ROH) Identified in Indian Patients with Autosomal Recessive Limb-Girdle Muscular Dystrophy with p.Thr182Pro Variant in SGCB Gene. Hum Mutat 2023. [DOI: 10.1155/2023/4362273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/30/2023]
Abstract
The sarcoglycanopathies are autosomal recessive limb-girdle muscular dystrophies (LGMDs) caused by the mutations in genes encoding the α, β, γ, and δ proteins which stabilizes the sarcolemma of muscle cells. The clinical phenotype is characterized by progressive proximal muscle weakness with childhood onset. Muscle biopsy findings are diagnostic in confirming dystrophic changes and deficiency of one or more sarcoglycan proteins. In this study, we summarized 1,046 LGMD patients for which a precise diagnosis was identified using targeted sequencing. The most frequent phenotypes identified in the patients are LGMDR1 (19.7%), LGMDR4 (19.0%), LGMDR2 (17.5%), and MMD1 (14.5%). Among the reported genes, each of CAPN3, SGCB, and DYSF variants was reported in more than 10% of our study cohort. The most common variant SGCB p.Thr182Pro was identified in 146 (12.5%) of the LGMD patients, and in 97.9% of these patients, the variant was found to be homozygous. To understand the genetic structure of the patients carrying SGCB p.Thr182Pro, we genotyped 68 LGMD patients using a whole genome microarray. Analysis of the array data identified a large ~1 Mb region of homozygosity (ROH) (chr4:51817441-528499552) suggestive of a shared genomic region overlapping the recurrent missense variant and shared across all 68 patients. Haplotype analysis identified 133 marker haplotypes that were present in ~85.3% of the probands as a double allele and absent in all random controls. We also identified 5 markers (rs1910739, rs6852236, rs13122418, rs13353646, and rs6554360) which were present in a significantly higher proportion in the patients compared to random control set (
) and the population database. Of note, admixture analysis was suggestive of greater proportion of West Eurasian/European ancestry as compared to random controls. Haplotype analysis and frequency in the population database indicate a probable event of founder effect. Further systematic study is needed to identify the communities and regions where the SGCB p.Thr182Pro variant is observed in higher proportions. After identifying these communities and//or region, a screening program is needed to identify carriers and provide them counselling.
Collapse
|